Novel strategies for treatment of follicular lymphoma
10.3760/cma.j.issn.1009-9921.2020.02.006
- VernacularTitle:滤泡淋巴瘤治疗新策略
- Author:
Zhangdi XU
1
;
Wei XU
Author Information
1. 南京医科大学第一附属医院 江苏省人民医院血液科 210029
- From:
Journal of Leukemia & Lymphoma
2020;29(2):91-94
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma (FL) is a kind of indolent non-Hodgkin lymphoma(iNHL). Rituximab combined with chemotherapy as the first-line treatment has achieved satisfactory results, but the relapse and progress still reappear after the first-line treatments. In the 61st of American Society of Hematology (ASH) Annual Meeting, more and more novel drugs including EZH2 inhibitor tazemetostat, SYK/JAK inhibitor cerdulatinib, anti-CD3-CD20 antibody mosunetuzumab and programmed death 1 inhibitor nivolumab, etc, and new strategies including rituximab combined with anti-CD20 monoclonal antibody and polatuzumab combined with obinutuzumab and lenalidomide had been reported and brought an ample and promising choices for FL patients.
